Comments
FDA panel recommends approval of Novo degludec insulin
09.11.2012. | (Reuters) - An advisory panel to the U.S. Food and Drug Administration on Thursday voted to recommend approval of Danish drugmaker Novo Nordisk's new ultra-long-acting insulin degludec, despite signals of possible cardiovascular risk....
